





Genomic Health INC
Rank 13 of 69

The relative strengths and weaknesses of Genomic Health INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Genomic Health INC compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 78% points. The greatest weakness of Genomic Health INC is the variable Selling and Marketing Expense, reducing the Economic Capital Ratio by 58% points.

The company's Economic Capital Ratio, given in the ranking table, is 248%, being 89% points above the market average of 159%.

Input Variable	Value in 1000 USD
Assets, Current	274,836
Assets, Non-Current	15,938
Cost of Goods and Services Sold	0
Depreciation, Depletion, Amortization	0
General and Administrative Expense	76,910
Goodwill Impairment Loss	0
Intangible Assets	0
Labor Expense	0
Liabilities, Current	59,776
Long Term Liabilities	0
Operating Costs and Expenses	0
Other Assets	4,066
Other Compr. Net Income	27
Other Expenses	65,573
Other Liabilities	0
Other Net Income	3,028
Other Revenues	394,111
Property Plant and Equipment	39,532
Research And Development Expense	64,200
Selling and Marketing Expense	164,779

Output Variable	Value in 1000 USD
Assets	334,372
Liabilities	59,776
Expenses	371,462
Revenues	394,111
Stockholders Equity	274,596
Net Income	25,677
Comprehensive Net Income	25,704
BaseVar	581,388
ECR before LimitedLiability	215%
Economic Capital Ratio	248%